Inherited thrombocytopenias: Toward a molecular understanding of disorders of platelet production

Current Opinion in Pediatrics

Volumn 16, Issue 1, 2004, Pages 15-22

  Geddis, Amy E ^a   Kaushansky, Kenneth ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Congenital; Hematopoiesis; Platelet; Thrombocytopenia

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; HUMAN; MAY HEGGLIN ANOMALY; MEGAKARYOCYTE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; REVIEW; SYNOSTOSIS; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; WISKOTT ALDRICH SYNDROME;

ANIMALS; BLOOD PLATELET DISORDERS; DNA-BINDING PROTEINS; GENETIC DISEASES, X-LINKED; HEMATOPOIETIC STEM CELLS; HOMEODOMAIN PROTEINS; HUMANS; MEGAKARYOCYTES; MUTATION; SYNDROME; THROMBOCYTOPENIA; THROMBOPOIESIS;

EID: 0842330260     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-200402000-00005     Document Type: Review

References (155)

1. Nurden AT, Caen JP: Specific roles for platelet surface glycoproteins in platelet function. Nature 1975, 255:720-722.
2. Muller AM, Medvinsky A, Strouboulis J, et al.: Development of hematopoietic stem cell activity in the mouse embryo. Immunity 1994, 1:291-301.
3. Godin I, Dieterlen-Lievre F, Cumano A: Emergence of multipotent hemopoietic cells in the yolk sac and paraaortic splanchnopleura in mouse embryos, beginning at 8.5 days postcoitus. Proc Natl Acad Sci USA 1995, 92:773-777.
4. Bartley TD, Bogenberger J, Hunt P, et al.: Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994, 77:1117-1124.
5. de Sauvage FJ, Hass PE, Spencer SD, et al.: Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994, 369:533-538.
6. Lok S, Foster DC: The structure, biology and potential therapeutic applications of recombinant thrombopoietin. Stem Cells 1994, 12:586-598.
7. Lok S, Kaushansky K, Holly RD, et al.: Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994, 369:565-568.
8. Sohma Y, Akahori H, Seki N, et al.: Molecular cloning and chromosomal localization of the human thrombopoietin gene. FEBS Lett 1994, 353:57-61.
9. Sitnicka E, Lin N, Priestley GV, et al.: The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells. Blood 1996, 87:4998-5005.
10. Kaushansky K: Mpl and the hematopoietic stem cell. Leukemia 2002, 16:738-739.
11. Solar GP, Kerr WG, Zeigler FC, et al.: Role of c-mpl in early hematopoiesis. Blood 1998, 92:4-10.
12. Balduini CL, Iolascon A, Savoia A: Inherited thrombocytopenias: from genes to therapy. Haematologica 2002, 87:860-880. An excellent review including a discussion of new treatment options for inherited thrombocytopenias.
13. Laurian Y: Treatment of bleeding in patients with platelet disorders: is there a place for recombinant factor VIIa? Pathophysiol Haemost Thromb 2002, 32(Suppl 1):37-40.
14. Blanchette VS, Sparling C, Turner C: Inherited bleeding disorders. Baillieres Clin Haematol 1991, 4:291-332.
15. Mhawech P, Saleem A: Inherited giant platelet disorders. Classification and literature review. Am J Clin Pathol 2000, 113:176-190.
16. Kaushansky K: CAMT: new findings and new questions. Blood 2001, 97:1-2.
17. Ballmaier M, Germeshausen M, Krukemeier S, Weite K: Thrombopoietin is essential for the maintenance of normal hematopoiesis in humans: development of aplastic anemia in patients with congenital amegakaryocytic thrombocytopenia. Ann N Y Acad Sci 2003, 996:17-25. Summarizes data regarding the role of TPO in maintaining the HSC compartment in both human CAMT and murine C-Mpl knockout models.
18. Mukai HY, Kojima H, Todokoro K, et al.: Serum thrombopoietin (TPO) levels in patients with amegakaryocytic thrombocytopenia are much higher than those with immune thrombocytopenic purpura. Thromb Haemost 1996, 76:675-678.
19. Nagata Y, Shozaki Y, Nagahisa H, et al.: Serum thrombopoietin level is not regulated by transcription but by the total counts of both megakaryocytes and platelets during thrombocytopenia and thrombocytosis. Thromb Haemost 1997, 77:808-814.
20. Ihara K, Ishii E, Eguchi M, et al.: Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci USA 1999, 96:3132-3136.
21. Tonelli R, Scardovi AL, Pession A, et al.: Compound heterozygosity for two different amino-acid substitution mutations in the thrombopoietin receptor (c-mpl gene) in congenital amegakaryocytic thrombocytopenia (CAMT). Hum Genet 2000, 107:225-233.
22. van den Oudenrijn S, Bruin M, Folman CC, et al.: Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia. Br J Haematol 2000, 110:441-448.
23. Ballmaier M, Germeshausen M, Schulze H, et al.: c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 2001, 97:139-146.
24. Alexander WS, Roberts AW, Maurer AB, et al.: Studies of the c-Mpl thrombopoietin receptor through gene disruption and activation. Stem Cells 1996, 14(Suppl 1):124-132.
25. Carver-Moore K, Broxmeyer HE, Luoh SM, et al.: Low levels of erythroid and myeloid progenitors in thrombopoietin-and c-mpl-deficient mice. Blood 1996, 88:803-808.
26. Kimura S, Roberts AW, Metcalf D, Alexander WS: Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. Proc Natl Acad Sci USA 1998, 95:1195-1200.
27. Murone M, Carpenter DA, de Sauvage FJ: Hematopoietic deficiencies in c-mpl and TPO knockout mice. Stem Cells 1998, 16:1-6.
28. Gurney AL, de Sauvage FJ: Dissection of c-Mpl and thrombopoietin function: studies of knockout mice and receptor signal transduction. Stem Cells 1996, 14(Suppl 1):116-123.
29. Thompson AA, Nguyen LT: Amegakaryocytic thrombocytopenia and radio-ulnar synostosis are associated with HOXA11 mutation. Nat Genet 2000, 26:397-398.
30. Thompson AA, Woodruff K, Feig SA, et al.: Congenital thrombocytopenia and radio-ulnar synostosis: a new familial syndrome. Br J Haematol 2001, 113:866-870.
31. Lawrence HJ, Sauvageau G, Humphries RK, Largman C: The role of HOX homeobox genes in normal and leukemic hematopoiesis. Stem Cells 1996, 14:281-291.
32. Magli MC, Largman C, Lawrence HJ: Effects of HOX homeobox genes in blood cell differentiation. J Cell Physiol 1997, 173:168-177.
33. Shimamoto T, Ohyashiki K, Toyama K, Takeshita K: Homeobox genes in hematopoiesis and leukemogenesis. Int J Hematol 1998, 67:339-350.
34. Thorsteinsdottir U, Sauvageau G, Humphries RK: Hox homeobox genes as regulators of normal and leukemic hematopoiesis. Hematol Oncol Clin North Am 1997, 11:1221-1237.
35. Bjornsson JM, Andersson E, Lundstrom P, et al: Proliferation of primitive myeloid progenitors can be reversibly induced by HOXA10. Blood 2001, 98:3301-3308.
36. Antonchuk J, Sauvageau G, Humphries RK: HOXB4 overexpression mediates very rapid stem cell regeneration and competitive hematopoietic repopulation. Exp Hematol 2001, 29:1125-1134.
37. Thorsteinsdottir U, Sauvageau G, Hough MR, et al.: Overexpression of HOXA10 in murine hematopoietic cells perturbs both myeloid and lymphoid differentiation and leads to acute myeloid leukemia. Mol Cell Biol 1997, 17:495-505.
38. Boulet AM, Capecchi MR: Duplication of the Hoxd11 gene causes alterations in the axial and appendicular skeleton of the mouse. Dev Biol 2002, 249:96-107.
39. Song WJ, Sullivan MG, Legare RD, et al.: Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999, 23:166-175.
40. Michaud J, Wu F, Osato M, et al.: In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood 2002, 99:1364-1372.
41. Wang Q, Stacy T, Miller JD, et al.: The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. Cell 1996, 87:697-708.
42. Okuda T, van Deursen J, Hiebert SW, et al.: AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996, 84:321-330.
43. Yergeau DA, Hetherington CJ, Wang Q, et al.: Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet 1997, 15:303-306. Mice heterozygous for and Runx-1-Eto allele were generated as a model of human t(8;21) leukemia, demonstrating the effect of this fusion protein on blocking normal Runx-1 function.
44. Wang Q, Stacy T, Binder M, et al.: Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci U S A 1996, 93:3444-3449.
45. Meyers S, Lenny N, Hiebert SW: The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol Cell Biol 1995, 15:1974-1982.
46. Downing JR: The core-binding factor leukemias: lessons learned from murine models. Curr Opin Genet Dev 2003, 13:48-54.
47. Tonks A, Pearn L, Tonks AJ, et al.: The AML1-ETO fusion gene promotes extensive self-renewal of human primary erythroid cells. Blood 2003, 101:624-632.
48. de Guzman CG, Warren AJ, Zhang Z, et al.: Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Mol Cell Biol 2002, 22:5506-5517.
49. Hug BA, Lee SY, Kinsler EL, et al.: Cooperative function of Aml1-ETO core-pressor recruitment domains in the expansion of primary bone marrow cells. Cancer Res 2002, 62:2906-2912.
50. Mulloy JC, Cammenga J, MacKenzie KL, et al.: The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood 2002, 99:15-23. Retroviral transduction is used to show that introduction of Runx-1 -Eto into human HSCs significantly enhanced HSC expansion at the expense of lineage commitment.
51. Okuda T, Cai Z, Yang S, et al.: Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood 1998, 91:3134-3143.
52. Rhoades KL, Hetherington CJ, Harakawa N, et al.: Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood 2000, 96:2108-2115.
53. Elagib KE, Racke FK, Mogass M, et al.: RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood 2003, 101:4333-4341. This work demonstrates an interaction between Gata-1 and Runx-1, a potential basis for the megakaryocytic phenotype seen in FPS/AML and in the transient abnormal myelopoiesis in Down syndrome.
54. Fox AH, Kowalski K, King GF, et al.: Key residues characteristic of GATA N-fingers are recognized by FOG. J Biol Chem 1998, 273:33595-33603.
55. Tsang AP, Visvader JE, Turner CA, et al.: FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation. Cell 1997, 90:109-119.
56. Visvader JE, Crossley M, Hill J, et al.: The C-terminal zinc finger of GATA-1 or GATA-2 is sufficient to induce megakaryocytic differentiation of an early myeloid cell line. Mol Cell Biol 1995, 15:634-641.
57. Whyatt DJ, deBoer E, Grosveld F: The two zinc finger-like domains of GATA-1 have different DNA binding specificities. EMBO J 1993, 12:4993-5005.
58. Freson K, Devriendt K, Matthijs G, et al.: Platelet characteristics in patients with X-linked macrothrombocytopenia because of a novel GATA1 mutation. Blood 2001, 98:85-92.
59. Freson K, Matthijs G, Thys C, et al.: Different substitutions at residue D218 of the X-linked transcription factor GATA1 lead to altered clinical severity of macrothrombocytopenia and anemia and are associated with variable skewed X inactivation. Hum Mol Genet 2002, 11:147-152.
60. Nichols KE, Crispino JD, Poncz M, et al.: Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1. Nat Genet 2000, 24:266-270.
61. Mehaffey MG, Newton AL, Gandhi MJ, et al.: X-linked thrombocytopenia caused by a novel mutation of GATA-1. Blood 2001, 98:2681-2688.
62. Yu C, Niakan KK, Matsushita M, et al.: X-linked thrombocytopenia with thalassemia from a mutation in the amino finger of GATA-1 affecting DNA binding rather than FOG-1 interaction. Blood 2002, 100:2040-2045.
63. Weiss MJ, Yu C, Orkin SH: Erythroid-cell-specific properties of transcription factor GATA-1 revealed by phenotypic rescue of a gene-targeted cell line. Mol Cell Biol 1997, 17:1642-1651.
64. McDevitt MA, Shivdasani RA, Fujiwara Y, et al.: A "knockdown" on created by cis-element gene targeting reveals the dependence of erythroid cell maturation on the level of transcription factor GATA-1. Proc Natl Acad Sci U S A 1997, 94:6781-6785.
65. Fujiwara Y, Browne CP, Cunniff K, et al.: Arrested development of embryonic red cell precursors in mouse embryos lacking transcription factor GATA-1. Proc Natl Acad Sci U S A 1996, 93:12355-12358.
66. Ohneda K, Yamamoto M: Roles of hematopoietic transcription factors GATA-1 and GATA-2 in the development of red blood cell lineage. Acta Haematol 2002, 108:237-245.
67. Shivdasani RA, Fujiwara Y, McDevitt MA, Orkin SH: A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J 1997, 16:3965-3973.
68. Tsang AP, Fujiwara Y, Hom DB, Orkin SH: Failure of megakaryopoiesis and arrested erythropoiesis in mice lacking the GATA-1 transcriptional cofactor FOG. Genes Dev 1998, 12:1176-1188.
69. Orkin SH: GATA-binding transcription factors in hematopoietic cells. Blood 1992, 80:575-581.
70. Vyas P, Ault K, Jackson CW, et al.: Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood 1999, 93:2867-2875.
71. Orkin SH, Shivdasani RA, Fujiwara Y, McDevitt MA: Transcription factor GATA-1 in megakaryocyte development. Stem Cells 1998, 16(Suppl 2):79-83.
72. Breton-Gorius J, Favier R, Guichard J, et al.: A new congenital dysmegakaryopoietic thrombocytopenia (Paris-Trousseau) associated with giant platelet alpha-granules and chromosome 11 deletion at 11q23. Blood 1995, 85:1805-1814.
73. Favier R, Douay L, Esteva B, et al.: A novel genetic thrombocytopenia (Paris-Trousseau) associated with platelet inclusions, dysmegakaryopoiesis and chromosome deletion AT 11q23. C R Acad Sci III 1993, 316:698-701.
74. Krishnamurti L, Neglia JP, Nagarajan R, et al.: Paris-Trousseau syndrome platelets in a child with Jacobsen's syndrome. Am J Hematol 2001, 66:295-299.
75. Ben-David Y, Giddens EB, Bernstein A: Identification and mapping of a common proviral integration site Fli-1 in erythroleukemia cells induced by Friend murine leukemia virus. Proc Natl Acad Sci USA 1990, 87:1332-1336.
76. Ben-David Y, Giddens EB, Letwin K, Bernstein A: Erythroleukemia induction by Friend murine leukemia virus: insertional activation of a new member of the ets gene family, Fli-1, closely linked to c-ets-1. Genes Dev 1991, 5:908-918.
77. Nye JA, Petersen JM, Gunther CV, et al.: Interaction of murine ets-1 with GGA-binding sites establishes the ETS domain as a new DNA-binding motif. Genes Dev 1992, 6:975-990.
78. Melet F, Motro B, Rossi DJ, et al.: Generation of a novel Fli-1 protein by gene targeting leads to a defect in thymus development and a delay in Friend virus-induced erythroleukemia. Mol Cell Biol 1996, 16:2708-2718.
79. Minami T, Tachibana K, Imanishi T, Doi T: Both Ets-1 and GATA-1 are essential for positive regulation of platelet factor 4 gene expression. Eur J Biochem 1998, 258:879-889.
80. Zhang L, Lemarchandel V, Romeo PH, et al.: The Fli-1 proto-oncogene, involved in erythroleukemia and Ewing's sarcoma, encodes a transcriptional activator with DNA-binding specificities distinct from other Ets family members. Oncogene 1993, 8:1621-1630.
81. Deveaux S, Filipe A, Lemarchandel V, et al.: Analysis of the thrombopoietin receptor (MPL) promoter implicates GATA and Ets proteins in the coregulation of megakaryocyte-specific genes. Blood 1996, 87:4678-4685.
82. Eisbacher M, Holmes ML, Newton A, et al.: Protein-protein interaction between Fli-1 and GATA-1 mediates synergistic expression of megakaryocyte- specific genes through cooperative DNA binding. Mol Cell Biol 2003, 23:3427-3441. The interaction between Fli-1 and Gata-1 is mapped and demonstrated to confer synergistic activation of megakaryocytic promoters in an in vitro system.
83. Athanasiou M, Clausen PA, Mavrothalassitis GJ, et al.: Increased expression of the ETS-related transcription factor FLI-1/ERGB correlates with and can induce the megakaryocytic phenotype. Cell Growth Differ 1996, 7:1525-1534.
84. Hart A, Melet F, Grossfeld P, et al.: Fli-1 is required for murine vascular and megakaryocytic development and is hemizygously deleted in patients with thrombocytopenia. Immunity 2000, 13:167-177.
85. Lu SJ, Rowan S, Bani MR, Ben-David Y: Retroviral integration within the Fli-2 locus results in inactivation of the erythroid transcription factor NF-E2 in Friend erythroleukemias: evidence that NF-E2 is essential for globin expression. Proc Natl Acad Sci U S A 1994, 91:8398-8402.
86. Ney PA, Andrews NC, Jane SM, et al.: Purification of the human NF-E2 complex: cDNA cloning of the hematopoietic cell-specific subunit and evidence for an associated partner. Mol Cell Biol 1993, 13:5604-5612.
87. Andrews NC, Erdjument-Bromage H, Davidson MB, et al.: Erythroid transcription factor NF-E2 is a haematopoietic-specific basic-leucine zipper protein. Nature 1993, 362:722-728.
88. Andrews NC, Kotkow KJ, Ney PA, et al.: The ubiquitous subunit of erythroid transcription factor NF-E2 is a small basic-leucine zipper protein related to the v-maf oncogene. Proc Natl Acad Sci USA 1993, 90:11488-11492.
89. Lecine P, Italiano JE Jr, Kim SW, et al.: Hematopoietic-specific beta 1 tubulin participates in a pathway of platelet biogenesis dependent on the transcription factor NF-E2. Blood 2000, 96:1366-1373.
90. Tiwari S, Italiano JE, Barrai DC, et al.: A role for Rab27b in NF-E2-dependent pathways of platelet formation. Blood 2003, in press.
91. Deveaux S, Cohen-Kaminsky S, Shivdasani RA, et al.: p45 NF-E2 regulates expression of thromboxane synthase in megakaryocytes. EMBO J 1997, 16:5654-5661.
92. Levin J, Peng JP, Baker GR, et al.: Pathophysiology of thrombocytopenia and anemia in mice lacking transcription factor NF-E2. Blood 1999, 94:3037-3047.
93. Shivdasani RA: The role of transcription factor NF-E2 in megakaryocyte maturation and platelet production. Stem Cells 1996, 14:112-115.
94. Shivdasani RA, Orkin SH: Erythropoiesis and globin gene expression in mice lacking the transcription factor NF-E2. Proc Natl Acad Sci U S A 1995, 92:8690-8694.
95. Shivdasani RA, Rosenblatt MF, Zucker-Franklin D, et al.: Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell 1995, 81:695-704.
96. Greenhalgh KL, Howell RT, Bottani A, et al.: Thrombocytopenia-absent radius syndrome: a clinical genetic study. J Med Genet 2002, 39:876-881.
97. Letestu R, Vitrat N, Masse A, et al.: Existence of a differentiation blockage at the stage of a megakaryocyte precursor in the thrombocytopenia and absent radii (TAR) syndrome. Blood 2000, 95:1633-1641.
98. Ballmaier M, Schulze H, Strauss G, et al.: Thrombopoietin in patients with congenital thrombocytopenia and absent radii: elevated serum levels, normal receptor expression, but defective reactivity to thrombopoietin. Blood 1997, 90:612-619.
99. Homans AC, Cohen JL, Mazur EM: Defective megakaryocytopoiesis in the syndrome of thrombocytopenia with absent radii. Br J Haematol 1988, 70:205-210.
100. de Alarcon PA, Graeve JA, Levine RF, et al.: Thrombocytopenia and absent radii syndrome: defective megakaryocytopoiesis-thrombocytopoiesis. Am J Pediatr Hematol Oncol 1991, 13:77-83.
101. Hall JG: Thrombocytopenia and absent radius (TAR) syndrome. J Med Genet 1987, 24:79-83.
102. Strippoli P, Savoia A, Iolascon A et al.: Mutational screening of thrombopoietin receptor gene (c-mpl) in patients with congenital thrombocytopenia and absent radii (TAR). Br J Haematol 1998, 103:311-314.
103. Ballmaier M, Schulze H, Cremer M, et al.: Defective c-Mpl signaling in the syndrome of thrombocytopenia with absent radii. Stem Cells 1998, 16:177-184.
104. Kovacsovics TJ, Hartwig JH: Thrombin-induced GPIb-IX centralization on the platelet surface requires actin assembly and myosin II activation. Blood 1996, 87:618-629.
105. Takafuta T, Wu G, Murphy GF, Shapiro SS: Human beta-filamin is a new protein that interacts with the cytoplasmic tail of glycoprotein Ibalpha. J Biol Chem 1998, 273:17531-17538.
106. Kanaji T, Russell S, Ware J: Amelioration of the macrothrombocytopenia associated with the murine Bernard-Soulier syndrome. Blood 2002, 100:2102-2107. Studies of the mouse model of BSS demonstrates that the cytoplasmic domain of GPIbα interacts with β-filamin and that reestablishment of this interaction partially corrects platelet size; however, a significant functional platelet defect remains, confirming the importance of the extracellular domain of GPIbα in hemostasis.
107. Savoia A, Balduini CL, Savino M, et al.: Autosomal dominant macrothrombocytopenia in Italy is most frequently a type of heterozygous Bernard-Soulier syndrome. Blood 2001, 97:1330-1335.
108. Kunishima S, Naoe T, Kamiya T, Saito H: Novel heterozygous missense mutation in the platelet glycoprotein Ib beta gene associated with isolated giant platelet disorder. Am J Hematol 2001, 68:249-255.
109. Nakagawa M, Okuno M, Okamoto N, et al.: Bernard-Soulier syndrome associated with 22q11.2 microdeletion. Am J Med Genet 2001, 99:286-288.
110. Budarf ML, Konkle BA, Ludlow LB, et al.: Identification of a patient with Bernard-Soulier syndrome and a deletion in the DiGeorge/velo-cardio-facial chromosomal region in 22q11.2. Hum Mol Genet 1995, 4:763-766.
111. Oda A, Ochs HD: Wiskott-Aldrich syndrome protein and platelets. Immunol Rev 2000, 178:111-117.
112. Rengan R, Ochs HD: Molecular biology of the Wiskott-Aldrich syndrome. Rev Immunogenet 2000, 2:243-255.
113. Ochs HD: The Wiskott-Aldrich syndrome. Semin Hematol 1998, 35:332-345.
114. Haddad E, Cramer E, Riviere C, et al.: The thrombocytopenia of Wiskott Aldrich syndrome is not related to a defect in proplatelet formation. Blood 1999 94:509-518.
115. Zhu Q, Watanabe C, Liu T, et al.: Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype. Blood 1997, 90:2680-2689.
116. de Saint Basile G, Lagelouse RD, Lambert N, et al.: Isolated X-linked thrombocytopenia in two unrelated families is associated with point mutations in the Wiskott-Aldrich syndrome protein gene. J Pediatr 1996, 129:56-62.
117. Notarangelo LD, Mazza C, Giliani S, et al.: Missense mutations of the WASP gene cause intermittent X-linked thrombocytopenia. Blood 2002, 99:2268-2269.
118. Derry JM, Ochs HD, Francke U: Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 1994, 79:following 922.
119. Villa A, Notarangelo L, Macchi P, et al.: X-linked thrombocytopenia and Wiskott-Aldrich syndrome are allelic diseases with mutations in the WASP gene. Nat Genet 1995, 9:414-417.
120. Schwarz K: WASPbase: a database of WAS- and XLT-causing mutations. Immunol Today 1 996, 17:496-502.
121. Shcherbina A, Rosen FS, Remold-O'Donnell E: WASP levels in platelets and lymphocytes of wiskott-aldrich syndrome patients correlate with cell dysfunction. J Immunol 1999, 163:6314-6320.
122. Weaver AM, Young ME, Lee WL, Cooper JA: Integration of signals to the Arp2/3 complex. Curr Opin Cell Biol 2003, 15:23-30.
123. Yarar D, To W, Abo A, Welch MD: The Wiskott-Aldrich syndrome protein directs actin-based motility by stimulating actin nucleation with the Arp2/3 complex. Curr Biol 1999, 9:555-558.
124. Welch MD: The world according to Arp: regulation of actin nucleation by the Arp2/3 complex. Trends Cell Biol 1999, 9:423-427.
125. Luthi JN, Gandhi MJ, Drachman JG: X-linked thrombocytopenia caused by a mutation in the Wiskott-Aldrich syndrome (WAS) gene that disrupts interaction with the WAS protein (WASP)-interacting protein (WIP). Exp Hematol 2003, 31:150-158.
126. Ramesh N, Anton IM, Hartwig JH, Geha RS: WIP, a protein associated with wiskott-aldrich syndrome protein, induces actin polymerization and redistribution in lymphoid cells. Proc Natl Acad Sci U S A 1997, 94:14671-14676.
127. Stewart DM, Tian L, Nelson DL: Mutations that cause the Wiskott-Aldrich syndrome impair the interaction of Wiskott-Aldrich syndrome protein (WASP) with WASP interacting protein. J Immunol 1999, 162:5019-5024.
128. Rohatgi R, Ho HY, Kirschner MW: Mechanism of N-WASP activation by CDC42 and phosphatidylinositol 4, 5-bisphosphate. J Cell Biol 2000, 150:1299-1310.
129. Symons M, Derry JM, Karlak B, et al.: Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization. Cell 1996, 84:723-734.
130. Devriendt K, Kim AS, Mathijs G, et al.: Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nat Genet 2001, 27:313-317.
131. Italiano JE Jr, Lecine P, Shivdasani RA, Hartwig JH: Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes. J Cell Biol 1999, 147:1299-1312.
132. Italiano JE Jr, Bergmeier W, Tiwari S, et al.: Mechanisms and implications of platelet discoid shape. Blood 2003, 101:4789-4796. A detailed description of the platelet cytoskeleton.
133. Hartwig J, Italiano J Jr: The birth of the platelet. J Thromb Haemost 2003, 1:1580-1586.
134. Boyles J, Fo JE, Phillips DR, Stenberg PE: Organization of the cytoskeleton in resting, discoid platelets: preservation of actin filaments by a modified fixation that prevents osmium damage. J Cell Biol 1985, 101:1463-1472.
135. Fox JE, Boyles JK, Reynolds CC, Phillips DR: Actin filament content and organization in unstimulated platelets. J Cell Biol 1984, 98:1985-1991.
136. Kenney DM, Linck RW: The cystoskeleton of unstimulated blood platelets: structure and composition of the isolated marginal microtubular band. J Cell Sci 1985, 78:1-22.
137. Kenney DM, Weiss LD, Linck RW: A novel microtubule protein in the marginal band of human blood platelets. J Biol Chem 1988, 263:1432-1438.
138. Falet H, Hoffmeister KM, Neujahr R, Hartwig JH: Normal Arp2/3 complex activation in platelets lacking WASp. Blood 2002, 100:2113-2122.
139. Seri M, Pecci A, Di Bari F, et al.: MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore) 2003, 82:203-215.
140. Heath KE, Campos-Barros A, Toren A, et al.: Nonmuscle myosin heavy chain UA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes. Am J Hum Genet 2001, 69:1033-1045.
141. Kawamoto S, Adelstein RS: Chicken nonmuscle myosin heavy chains: differential expression of two mRNAs and evidence for two different polypeptides. J Cell Biol 1991, 112:915-924.
142. Lalwani AK, Goldstein JA, Kelley MJ, et al.: Human nonsyndromic hereditary deafness DFNA17 is due to a mutation in nonmuscle myosin MYH9. Am J Hum Genet 2000, 67:1121-1128.
143. Toothaker LE, Gonzalez DA, Tung N, et al.: Cellular myosin heavy chain in human leukocytes: isolation of 5′ cDNA clones, characterization of the protein, chromosomal localization, and upregulation during myeloid differentiation. Blood 1991, 78:1826-1833.
144. Sellers JR: Myosins: a diverse superfamily. Biochim Biophys Acta 7000, 1496:3-22.
145. Di Pumpo M, Noris P, Pecci A, et al.: Defective expression of GPIb/IX/V complex in platelets from patients with May-Hegglin anomaly and Sebastian syndrome. Haematologica 2002, 87:943-947.
146. Gandhi MJ, Cummings CL, Drachman JG: FLJ14813 missense mutation: a candidate for autosomal dominant thrombocytopenia on human chromosome 10. Hum Hered 2003, 55:66-70. This identification of a new kinase in megakaryocytes suggests that much can still be learned from investigation of families with inherited thrombocytopenia.
147. Gilman AL, Sloand E, White JG, Sacher R: A novel hereditary macrothrombocytopenia. J Pediatr Hematol Oncol 1995, 17:296-305.
148. Raccuglia G: Gray platelet syndrome. A variety of qualitative platelet disorder. Am J Med 1971, 51:818-828.
149. Breton-Gorius J, Vainchenker W, Nurden A, et al.: Defective alpha-granule production in megakaryocytes from gray platelet syndrome: ultrastructural studies of bone marrow cells and megakaryocytes growing in culture from blood precursors. Am J Pathol 1981, 102:10-19.
150. Levy-Toledano S, Caen JP, Breton-Gorius J, et al.: Gray platelet syndrome: alpha-granule deficiency. Its influence on platelet function. J Lab Clin Med 1981, 98:831-848.
151. Drouin A, Favier R, Masse JM, et al.: Newly recognized cellular abnormalities in the gray platelet syndrome. Blood 2001, 98:1382-1391.
152. Srivastava PC, Powling MJ, Nokes TJ, et al.: Grey platelet syndrome: studies on platelet alpha-granules, lysosomes and defective response to thrombin. Br J Haematol 1987, 65:441-446.
153. Green D, Ts'ao CH, Cohen I, Rossi EC: Haemorrhagic thrombocytopathy associated with dilatation of the platelet-membrane complex. Br J Haematol 1981, 48:595-600.
154. Milton JG, Frojmovic MM, Tang SS, White JG: Spontaneous platelet aggregation in a hereditary giant platelet syndrome (MPS). Am J Pathol 1984, 114:336-345.
155. Okita JR, Frojmovic MM, Kristopeit S, et al.: Montreal platelet syndrome: a defect in calcium-activated neutral proteinase (calpain). Blood 1989, 74:715-721.